levoleucovorin and Remission--Spontaneous

Topics: Adolescent; Adult; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma; Methotrexate; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Remission, Spontaneous; Vincristine

Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Recurrence; Remission, Spontaneous; Research Design; Time Factors; Transplantation, Autologous

Patients with malignant lymphoma, diffuse type, have an unfavorable prognosis when compared to those patients with modular patterns. Prior to the introduction of combination chemotherapy, 50% survival rates for MC-D or PDL-D were about 2 years, HL-D about 1 year. Aggressive combination chemotherapy for advanced MC-D or PDL-D results in complete remission rates of 22-82%, with median survivals of 1-2 years. Patients with localized HL-D are probably curable with radiotherapy alone in 75% of cases. Patients with advanced disease are best treated with intensive combination chemotherapy, achieving a long-lasting complete remission in over one-half of cases, with median survivals now at 1-3 years. Many of these patients are probably cured, central nervous system relapse may now be a concern. The results of treatment of advanced histiocytic lymphoma are now approaching the results reported for advanced Hodgkin disease.

Topics: Antineoplastic Agents; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Leucovorin; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Methotrexate; Neoplasms; Prednisone; Remission, Spontaneous; Vincristine

Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Burkitt Lymphoma; Child; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Leucovorin; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Remission, Spontaneous; Time Factors

A randomized trial of combined modality therapy employing combination chemotherapy (cyclophosphamide (CTX) and methotrexate (MTX), CTX, MTX and Vincristine (VCR) and CTX, VCR and high-dose MTX with citrovorum rescue) and radiation therapy was compared to cyclophosphamide and radiation therapy in 258 patients with pulmonary small cell carcinoma. Patients were also rendomized: 1) to determine the effects of prophylactic whole brain irradiation; and 2) to establish the effects of maintenance chemotherapy. Survival, frequency of response and site of relapse were different in patients with limited disease (LD) (disease confined to lung, mediastinum and supraclavicular lymph nodes) when compared with disease spread beyond these sites (extensive disease) (ED). No survival advantage was seen in LD when combination chemotherapy was employed, although the frequency of complete remission was greater with three drugs than with one or two drugs (40% vs. 32%). In ED frequency of response was greater for three drugs than for one and two drugs (60% vs. 40%), but there was no survival advantage. The median survival time for complete responders was similar for limited or extensive disease (12.1 months), but 23.8% were alive at 24 months with LD compared to none with ED. Maintenance chemotherapy significantly prolonged survival by 16.8 months with 33% alive at 24 months compared to 9% who were unmaintained. Prophylactic while brain irradiation prevented brain metastases with only 4% developing this complication as compared to 18% of control subjects, but did not influence survival.

Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leucovorin; Lung Neoplasms; Male; Methotrexate; Middle Aged; Random Allocation; Remission, Spontaneous; Time Factors; Vincristine

Eight patients with epidermoid carcinoma of the penis received methotrexate, five with high-dose methotrexate, 250--1500 mg/m2 with citrovorum rescue Q 2--4 weeks, and three with low-dose methotrexate, 0.5--3.0 mg/kg weekly. Three (38%) patients achieved a complete or partial remission which persisted for 11, 3 and 2 months, respectively. Methotrexate appears to be an active agent in the treatment of advanced penile cancer.

Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Penile Neoplasms; Remission, Spontaneous; Time Factors

Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Recurrence; Remission, Spontaneous; Research Design; Time Factors; Transplantation, Autologous

Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Burkitt Lymphoma; Child; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Leucovorin; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prognosis; Remission, Spontaneous; Time Factors

Six adults with refractory acute lymphocytic leukemia (ALL) were treated with high-dose methotrexate, citrovorum factor, and vincristine. All patients had previously received extensive treatment with standard therapeutic agents, including vincristine, and all but one had received prior methotrexate. Two patients achieved complete remission and one achieved partial remission. Responses were seen at 3--6 gm/m2 of methotrexate. The durations of remission were 7--10 weeks. High-dose methotrexate with citrovorum factor is effective in the treatment of advanced ALL and should be considered for inclusion in initial combination chemotherapeutic regimens for adult ALL.

Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Leucovorin; Leukemia, Lymphoid; Methotrexate; Middle Aged; Remission, Spontaneous; Time Factors; Vincristine

Thirty patients with diffuse histiocytic lymphoma (DHL) were treated with one of three regimens that included cyclophosphamide, vincristine, methotrexate with citrovorum factor rescue, and cytosine arabinoside. Twelve patients had a complete response with a predicted 50% survival of at least 76 months. The medium survival of the 11 partial responders and seven nonresponders was 18 and 6 months, respectively. The addition of methotrexate and cytosine arabinoside may have a beneficial effect in therapy for DHL. From analysis of these results, there is reason to believe that efficacy may be partially dependent on the scheduling and dose of these two drugs.

Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Recurrence; Remission, Spontaneous; Time Factors; Vincristine

Fifteen patients with nonmetastatic gestational trophoblastic neoplasms were treated primarily with methotrexate and citrovorum factor. Complete and sustained remission was achieved in 14 of the 15 patients. Response to treatment was determined solely on the basis of serial serum human chorionic gonadotropin levels as measured by the beta subunit radioimmunoassay. All patients developed nonmetastatic gestational trophoblastic neoplasms following evacuation of a molar pregnancy. The known histologic diagnosis in all cases was hydatidiform mole. No significant toxicity was encountered despite careful monitoring of marrow, hepatic, renal, neurologic, and mucocutaneous parameters. Up to January 31, 1976, duration of remission ranged from 2 to 14 months.

Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Hydatidiform Mole; Leucovorin; Methotrexate; Parity; Pregnancy; Remission, Spontaneous; Trophoblastic Neoplasms; Uterine Neoplasms

The relationship between changes in the bone marrow labeling index and the patient's subsequent response to cycle-specific agents was studied by the South-eastern Cancer Study Group in adults with acute leukemia. Ninety-eight patients were randomized to one of two treatment regimens. Schedule 1 consisted of a single intravenous (i.v.) push of cytosine arabinoside followed in 48 hours by a large dose of oral methotrexate distributed over 24 hours and i.v. vincristine. Leucovorin rescue was employed to control the toxic effects of the high dose methotrexate and the cycle was repeated every 7 days. Schedule 2 differed only in that there were three daily injections of cytosine arabinoside preceding vincristine and methotrexate injections and each cycle was given every 10 days. Cell kinetic studies were performed in 30 patients and revealed that the majority of patients who had a response to therapy had some increase in the marrow labeling index 48 hours after cytosine arabinoside injection. In general, those patients who had no response to therapy had little change. There was no significant difference between schedules in the ability to induce an increase in labeling index 48 hours after cytosine arabinoside or in the increment achieved by the responders. However, there was a significant difference in the response rate seen with these schedules. Schedule 1 achieved only a 24% remission rate in acute nonlymphocytic leukemia (ANLL) while schedule 2 was associated with a 52% remission rate. In acute lymphoblastic leukemia (ALL) both schedules induced a 60% remission rate while none of the four patients with blast crisis of chronic granulocytic leukemia (CGL) responded. Analysis of the characteristics associated with remission revealed that more females achieved a remission than males and that the presence of pretreatment infection was the greatest contributing cause of early death and thus severely limited the ability to achieve a remission. As opposed to the current regimens used in ANLL, schedule 2 did not require significant bone marrow hypoplasia (as judged by the degree of hematological toxicity) to achieve a remission and there was no decrease in response seen with increasing age. The data suggest that increased efficiency of cycle-specific, antitumor agents may occur by increasing the proportion of human leukemic cells in DNA synthesis.

Topics: Adult; Age Factors; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cytarabine; Female; Humans; Leucovorin; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Sex Factors; Vincristine

Topics: Adolescent; Adult; Aged; Agranulocytosis; Alopecia; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Combinations; Female; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Nervous System Diseases; Radiography, Thoracic; Remission, Spontaneous; Vincristine

One hundred and ninety-one cases of acute lymphoblastic leukaemia were entered in a trial in which, for five months, all received cytotoxic therapy with prednisolone, vincristine, mercaptopurine, L-asparaginase, and methotrexate (the latter in high dosage followed by folinic acid). Patients were then randomized to receive immunotherapy (B.C.G.), twice-weekly methotrexate, or no further treatment.One hundred and seventy-seven patients (93%) achieved full remission and at the time of analysis, 26 months from the beginning of the trial, 143 were still alive, including 70 in their first remission. Median "post-intensive" remission lengths were 17 weeks (no treatment), 27 weeks (B.C.G.), and 52 weeks (methotrexate). The prolongation of remission by methotrexate was most evident in those patients with low initial white cell counts. B.C.G. seemed to cause lymphocytosis but was without other conspicuous effect. The incidence of toxic reactions is reported, including an unusually low rate of anaphylaxis with L-asparaginase.These preliminary results are discussed and compared with those of similar trials.

Topics: Acute Disease; Adolescent; Adult; Anaphylaxis; Asparaginase; BCG Vaccine; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant; Leucovorin; Leukemia, Lymphoid; Leukocyte Count; Lymphocytes; Lymphocytosis; Mercaptopurine; Methotrexate; Prednisolone; Remission, Spontaneous; Skin Tests; Tuberculin Test; Vincristine

The case of a six year old girl with metastatic (or primarily multifocal) osteogenic sarcoma is reported, which was treated with chemotherapy only. Within 15 months--the primary tumor regressed and at least a transient inactivation has resulted until now;--the pulmonary metastases showed no progression;--an osteoplastic destruction of the sacrum has completely regressed. At the time of report (15 months after initiation of treatment) neither on X-ray controls nor on bone scan signs of tumor regrowth are evident. The child is without any complaints and the leg has no loss of function.

Topics: Antineoplastic Agents; Child; Doxorubicin; Drug Therapy, Combination; Female; Femoral Neoplasms; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Neoplasm Metastasis; Osteosarcoma; Radiography; Remission, Spontaneous; Sacrum; Vincristine

Thirty-five patients with nometastatic gestational trophoblastic neoplasms and 3 patients with metastatic gestational trophoblastic neoplasms were treated primarily with methotrexate and citrovorum factor rescue. The antecedent pregnancy was molar in all patients. The known histologic diagnosis in 34 patients was hydatdiform mole and choriocarcinoma in 3. Up to March 1977, the duration of remissions ranged from 1 to 21 months. Complete and sustained remission was achieved in 91% of patients with nonmetastatic disease and in 2 of the 3 patients with metastases, without evidence of marrow or hepatic and with substantially reduced epithelial toxicity. Response to treatment and the number of courses required to achieve remission were determined solely on the basis of the human chorionic gonadotropin response as measured by the beta subunit radioimmunoassay.

Topics: Adolescent; Adult; Bone Marrow; Chemical and Drug Induced Liver Injury; Chorionic Gonadotropin; Drug Therapy, Combination; Epithelium; Female; Humans; Leucovorin; Liver; Methotrexate; Middle Aged; Neoplasm Metastasis; Pregnancy; Pregnancy Complications; Remission, Spontaneous; Trophoblastic Neoplasms; Uterine Neoplasms

A patient with oat cell carcinoma of the larynx with metastasis to cervical lymph nodes is presented. Treatment with radiation and chemotherapy has achieved a sustained remission. Pretherapy staging and combined modality therapy are discussed.

Topics: Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Laryngeal Neoplasms; Leucovorin; Lymphatic Metastasis; Male; Methotrexate; Neck; Radiotherapy Dosage; Remission, Spontaneous

Biopsy specimens from a 21-year-old man showed mycosis fungoides involving the skin and lungs. Usually such a case represents a fulminant and fatal course of the disease. This patient had a complete remission of his pulmonary disease following sequential therapy with cyclophosphamide, vincristine sulfate, methotrexate, leucovorin calcium, and cytarabine (COMLA).

Topics: Adult; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Leucovorin; Lung Neoplasms; Male; Methotrexate; Mycosis Fungoides; Remission, Spontaneous; Skin Neoplasms; Vincristine

Thirteen patients with metastatic squamous cell cancer of the lung were treated, in a nonrandomized study, with an oral high-dose methotrexate and citrovorum factor rescue regimen. There was some response and/or stabilization of disease for at least three months in six (46%) of 13 cases. The median survival time of the study group was double (365 vs. 180 days) that of a retrospectively matched control group. This suggests a possible therapeutic effect of this treatment program in metastatic squamous cell cancer of the lung.

Topics: Administration, Oral; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Humans; Leucovorin; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Time Factors

The results of treating 59 patients with advanced carcinoma of the cervix with Adriamycin and methotrexate are given. Five combinations of the two cytotoxic drugs have been evaluated, differing only with regard to the methotrexate. One particular regimen has been shown to be effective with a relatively high remission rate coupled with a low rate of side effects.

Topics: Alopecia; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Leucovorin; Leukopenia; Methotrexate; Mouth Diseases; Remission, Spontaneous; Taste Disorders; Ulcer; Uterine Cervical Neoplasms

Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Leucovorin; Methotrexate; Neoplasm Metastasis; Osteosarcoma; Remission, Spontaneous; Sarcoma, Ewing; Vincristine

Topics: Adult; Aged; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Prednisone; Remission, Spontaneous; Vincristine

Vincristine-high-dose methotrexate-citrovorum factor (VCR-MTX-CF) was administered preoperatively at weekly intervals to eight patients, four with primary tumors and four with pulmonary metastases. These patients had not received prior VCR-MTX-CF treatment. A similar treatment program was administered to five patients with pulmonary metastases who had received prior VCR-MTX-CF. Among the eight patients who had not received prior VCR-MTX-CF, complete responses were obtained in three with primary tumors (this was followed by surgical excision) and two with pulmonary metastases. Partial responses occurred in two additional patients. Partial responses were also obtained in two patients who had received VCR-MTX-CF. Chemotherapy and surgery in one patient with an extremity lesion resulted in preservation of the limb and useful function. The major toxicity was anorexia and weight loss. Other side effects included stomatitis, myelosuppression, hepatitis and transient renal impairment. The weekly program was highly effective when compared to responses obtained with the tri-weekly schedule utilized in previous studies.

Topics: Bone Neoplasms; Drug Administration Schedule; Humans; Leucovorin; Lung Neoplasms; Male; Methotrexate; Neoplasm Metastasis; Osteosarcoma; Remission, Spontaneous; Vincristine

Modern treatment of childhood dermatomyositis with corticosteroids has resulted in greatly improved prognosis and style of life. The immunosuppressive drugs methotrexate and azathioprine have been utilized as ancillary agents in life-threatening disease and in children whose disease could not be adequately controlled with prednisone alone. Two patients are completely well without medication two and seven years after onset; two have received no medications for more than two years and have only subtle signs of any residual illness although they had been profoundly ill for two to three years after the onset of dermatomyositis. A fifth patient, completing the third year of disease, remains ill and continues to require medications but has improved sufficiently to return to regular class in school.

Topics: Azathioprine; Child; Child, Preschool; Dermatomyositis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Leucovorin; Male; Methotrexate; Prednisone; Remission, Spontaneous

Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, methotrexate with leucoverin rescue) in 32 patients with metastatic carcinoma of the breast resulted in an overall response rate of 81 per cent (9/32 complete remission, 17/32 partial remission). No serious side effects were noted. Karnofsky performance index improved in 24/26 responders.

Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leucovorin; Lymphatic Metastasis; Methotrexate; Neoplasm Metastasis; Remission, Spontaneous; Vincristine

The combination of adriamycin, 5-fluorouracil and methotrexate with folinic acid reversal was used to treat patients with advanced bronchogenic carcinoma. Twenty-one of 30 patients showed an objective response. This combination appears to produce useful remissions in patients with non-squamous lung cancer.

Topics: Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Time Factors

Topics: Bone Marrow; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leucovorin; Male; Neoplasms; Pyrimethamine; Remission, Spontaneous

Fifty patients with metastatic breast cancer were treated with 8-day courses of vincristine (1 mg iv, Day 1), adriamycin (50 mg/m2 iv, Day 1), cyclophosphamide (100 mg/m2 orally, Days 1-8), methotrexate (200 mg iv by 3-hour infusion, Day 8), and citrovorum factor rescue (15 mg in 12, 18, and 24 hours after methotrexate, Day 8) at 3-4-week intervals. Forty-two patients had previously received treatment with hormones and 17 patients had received chemotherapy. Fifteen patients achieved a complete remission (CR) and 24 patients a partial remission (PR). There was a significant correlation between the response and the number of metastatic organs (0.01 less than P less than 0.02). The response rate was roughly uniform irrespective of the organ predominantly involved (0.2 less than P less than 0.3). The remission duration was significantly longer for the patients with CR compared with that for the patients with PR (0.001 less than P less than 0.01). The patients who achieved CRs and PRs survived significantly longer than the patients with no change and progressive disease (P less than 0.001). The toxic effects of the treatment were acceptable and no drug-related deaths occurred.

Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leucovorin; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Remission, Spontaneous; Vincristine

Seven adult patients with advanced lymphoma, resistant to vincristine, prednisone, alkylating agents and Adriamycin were treated with "high dose" methotrexate and citrovorum factor rescue. Therapy consisted of 4 to 6-hour infusions of methotrexate (5--100 mg/kg) every 1 to 2 weeks with citrovorum rescue initiates 2 to 12 hours after termination of the infusion. Objective responses were obtained in three patients but these were short lived. Mucosal and hematologic toxicity occurred when repeat courses of therapy were administered. The results suggest that high dose methotrexate may be effective therapy in lymphoma, particularlly if citrovorum factor rescue is used early and in adequate dosage.

Topics: Adolescent; Aged; Antineoplastic Agents; Bone Marrow; Drug Resistance; Drug Therapy, Combination; Female; Humans; Infusions, Parenteral; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Stomatitis; Time Factors

High doses of methotrexate (HDMTX), given in pulse infusions of 3 to 30 mg/kg body weight, were studied in 22 children with non-Hodgkin's lymphoma. Sixteen complete and five partial remissions were observed in 21 patients evaluable for remission induction. The dose of MTX was increased stepwise on consecutive treatments until objective tumor response occured. Citrovorum factor rescue (CFR) was used "on demand" when toxicity started to develop, and routinely after 30 mg/kg of MTX. Twelve patients who had no previous chemotherapy were entered in a Phase II study consisting of remission induction with HDMTX and remission maintenance with monthly HDMTX supplemented with one monthly injection of vincristine and Cytoxan and five days of oral 6-mercaptopurine and prednisone. Eleven patients achieved remissions (eight complete and three partial) with HDMTX and one with surgery and radiation followed by HDMTX. The three partial remissions improved to complete remission during remission maintenance. All 12 were given the maintenance cyclic combination chemotherapy. Seven of the 12 patients entered the unmaintained phase of the study. One patient relapsed 6 months after cessation of therapy and died 4 years after diagnosis. Six patients are alive and free of disease 2 1/2 to 5 1/2 years after discountinuing treatment and 4 1/2 to 8 1/3 years after diagnosis. Five of these six patients had advanced (Stage IV) disease.

Topics: Child; Humans; Infusions, Parenteral; Leucovorin; Lymphoma, Non-Hodgkin; Methotrexate; Remission, Spontaneous

The results obtained with protracted intra-arterial chemotherapy infusions in 60 case of primary or secondary liver tumor are discussed. The treatment should if possible be associated with surgical excision of the dominant tumor mass. Subjective improvement is obtainable in 75% of cases and objective improvement (including longer survival) in 50%. In some exceptionally favourable cases complete histologic disappearance of the metastases has also been achieved. Carcinoembryonic antigen determination appears to be the most reliable follow-up test.

Topics: Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Floxuridine; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Methods; Methotrexate; Remission, Spontaneous; Vincristine

Short treatment with four cytostatics in acute granulocytic leukemia induced aplasia and reduction of total leukemic cells in 50 over 59 patients. Complete remission occured in 30 and 20 died with infectious complications during induction. Short induction treatment allowed a reduction of induction period and so a reduction of high risk period of induction before completion of complete remission.

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Fever; Hemorrhage; Humans; Leucovorin; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Pyruvaldehyde; Remission, Spontaneous; Sepsis

Topics: Amidines; Drug Combinations; Drug Interactions; Humans; Leucovorin; Leukemia; Pentamidine; Pneumonia, Pneumocystis; Pyrimethamine; Remission, Spontaneous; Sulfadiazine

Seventeen patients with Stage III or IV reticulum cell sarcoma were treated with three cycles of a 5-drug regimen between February, 1969 and December, 1970. Of the 17 patients, 9 attained a complete remission and 6 had a parital remission; 2 were considered unevaluable. Recently, the original biopsies from these patients were reclassified according to the criteria of rappaport et al. The results were: diffuse histiocytic--8; nodular histiocytic--2; diffuse mixed--2; nodular mixed--3; diffuse lymphocytic poorly differentiated--1; nodular lymphocytic poorly differentiated--1. Of the 8 patients with diffuse histiocytic lymphoma 6 attained complete remission, 1 had a partial remission, and 1 was unevaluable. One of the 6 with complete remission relapsed at 7 months and died 2 months later. However, the other 5 are alive and in continued unmaintained remission for 55 to 65 months.

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Retrospective Studies; Time Factors; Vincristine

Topics: Aerobiosis; Animals; Carcinoma 256, Walker; Dietary Carbohydrates; Energy Metabolism; Extracellular Space; Female; Glucose; Glycolysis; Hydrogen-Ion Concentration; Hypoxia; Injections, Subcutaneous; Lactates; Leucovorin; Ligation; Methotrexate; Neoplasm Transplantation; Phrenic Nerve; Pulmonary Artery; Rats; Remission, Spontaneous

Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Cells; Cell Biology; Cell Survival; Child; DNA, Neoplasm; Humans; In Vitro Techniques; Leucovorin; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukocytes; Methotrexate; Purines; Remission, Spontaneous; Thymidine; Tritium

Topics: Administration, Oral; Brain Neoplasms; Calcium; Child; Drug Evaluation; Glioma; Humans; Infusions, Parenteral; Leucovorin; Male; Methotrexate; Neoplasm Recurrence, Local; Pons; Remission, Spontaneous

Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Catheterization; Cyclophosphamide; Glutamates; Head and Neck Neoplasms; Humans; Hydroxyurea; Infusions, Parenteral; Injections, Intravenous; Leucovorin; Methotrexate; Mouth Neoplasms; Pteridines; Remission, Spontaneous

Topics: Adult; Aged; Breast Neoplasms; Ear Neoplasms; Female; Humans; Injections, Intramuscular; Injections, Intravenous; Injections, Subcutaneous; Kinetics; Laryngeal Neoplasms; Leucovorin; Male; Methotrexate; Middle Aged; Nose Neoplasms; Remission, Spontaneous

Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Evaluation Studies as Topic; Female; Humans; Leucovorin; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Remission, Spontaneous; Time Factors

Topics: Cytosine; Daunorubicin; Drug Synergism; Drug Therapy, Combination; Glyoxal; Humans; Leucovorin; Leukemia, Myeloid, Acute; Methotrexate; Remission, Spontaneous

Topics: Adolescent; Adult; Age Factors; Aged; Amantadine; Asparaginase; BCG Vaccine; Child; Child, Preschool; Cytarabine; Humans; Hydrocortisone; Immunity, Active; Immunization, Passive; Immunotherapy; Infant; Leucovorin; Leukemia, Lymphoid; Mercaptopurine; Methotrexate; Middle Aged; Prednisone; Radiotherapy, High-Energy; Remission, Spontaneous; Vincristine

Topics: Humans; Leucovorin; Methotrexate; Neoplasm Metastasis; Remission, Spontaneous; Sarcoma

Topics: Breast Neoplasms; Choriocarcinoma; Female; Head; Head and Neck Neoplasms; Humans; Leucovorin; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Methotrexate; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Pregnancy; Remission, Spontaneous; Uterine Cervical Neoplasms

Topics: Ampicillin; Bone Marrow Diseases; Child; Cloxacillin; Female; Humans; Inhalation; Injections, Intramuscular; Leucovorin; Leukemia, Lymphoid; Lung; Methotrexate; Pneumonia; Prednisone; Remission, Spontaneous; Vincristine